BioSpace News Archive

Paradigm Therapeutics Inc., a biopharmaceutical company, today announced the completion of the acquisition of the worldwide rights of SD-101, a topical whole-body treatment for all subtypes of Epidermolysis Bullosa (EB), from Amicus Therapeutics.

Zimmer Biomet Holdings, Inc. today announced the appointment of Ivan Tornos as President and Chief Executive Officer (CEO) and election to the Board of Directors, effective immediately.

Verismo Therapeutics , a clinical-stage CAR T company, Penn spinout, and pioneer of the novel KIR-CAR platform technology, today announced that it had entered into a licensing agreement with the University of Pennsylvania.

Crown Bioscience has announced that its collaborative work with HanX Biopharmaceutical Co., Ltd. (“HanX”), employing a unique and broad portfolio of preclinical modeling in support of HanX’s successful FDA Investigational New Drug (IND) application, has been published in Scientific Reports, a journal within the Nature portfolio.

Levita Magnetics, whose mission is to help more patients get access to better surgery, announced today it has received U.S. Food and Drug Administration (FDA) clearance for its MARS™ platform.

Bredis Healthcare, Inc. announced that they have been selected by South Korea’s Ministry of SMEs and Startups to receive its Deep Tech TIPS grant.

InDex Pharmaceuticals Holding AB announced that the positive results from the pharmacokinetic study with cobitolimod in patients with moderate to severe ulcerative colitis will be presented at one of the leading gastroenterology conferences, the United European Gastroenterology Week.

BaroPace Inc. announced that the first patient has been enrolled in the Company’s First-in-Human clinical trial, RelieveHFpEF-II.

Neuronascent Inc., a privately-held neuron regeneration therapeutics company, announced that the National Institute of Aging, has awarded a U01 grant to Neuronascent, with the CEO, Dr. Judith Kelleher-Andersson being the principal investigator.

Medtronic plc announced financial results for its first quarter of fiscal year 2024, which ended July 28, 2023.